Last €5.55 EUR
Change Today -0.432 / -7.22%
Volume 200.0
P09 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:49 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

pacific biosciences of calif (P09) Snapshot

Open
€5.95
Previous Close
€5.98
Day High
€6.02
Day Low
€5.55
52 Week High
01/28/15 - €7.50
52 Week Low
04/15/14 - €2.86
Market Cap
430.6M
Average Volume 10 Days
90.0
EPS TTM
--
Shares Outstanding
77.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PACIFIC BIOSCIENCES OF CALIF (P09)

pacific biosciences of calif (P09) Related Bloomberg News

View More Bloomberg News

pacific biosciences of calif (P09) Related Businessweek News

View More BusinessWeek News

pacific biosciences of calif (P09) Details

Pacific Biosciences of California, Inc. develops, manufactures, and markets an integrated platform for genetic analysis in the deoxyribonucleic acid (DNA) sequencing market. The company is engaged in developing a single molecule real-time (SMRT) technology for the detection of biological processes. Its SMRT technology is used to study the synthesis, composition, structure, and regulation of DNA, as well as to record individual biochemical events as they occur. The company’s product includes the PacBio RS II high resolution genetic analyzer, an instrument that conducts, monitors, and analyzes single molecule biochemical reactions in real time. Its PacBio RS high resolution genetic analyzer consists of an instrument platform that uses its proprietary consumables, such as SMRT Cells and reagent kits to prepare and sequence DNA samples. The company’s customers include genome centers, genomics service providers, and pharmaceutical and agricultural companies, as well as clinical, government, and academic institutions. Pacific Biosciences of California, Inc. markets its products through a direct sales force in North America and Europe, as well as through distributors in Asia. The company, formerly known as Nanofluidics, Inc., was founded in 2000 and is headquartered in Menlo Park, California.

344 Employees
Last Reported Date: 02/3/15
Founded in 2000

pacific biosciences of calif (P09) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: $1.0
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.0
Senior Vice President of Market Development
Total Annual Compensation: $361.5K
Senior Vice President of Research and Develop...
Total Annual Compensation: $361.5K
Compensation as of Fiscal Year 2013.

pacific biosciences of calif (P09) Key Developments

Pacific Biosciences of California, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenue Guidance for the First Quarter and Full Year of 2015

Pacific Biosciences of California, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of $16,904,000 against $9,134,000 a year ago. Operating loss was $17,894,000 against $17,004,000 a year ago. Net loss was $18,975,000 or $0.26 per basic and diluted share against net loss of $17,231,000 or $0.26 per basic and diluted share a year ago. Fourth quarter 2014 revenue reflects the delivery of 15 PacBio® RS II Sequencing instruments, compared to five instruments during the fourth quarter of 2013. Higher revenue in the fourth quarter of 2014 led to the increase in gross profit, while the higher mix of revenue from instruments, which has lower margins than other revenue segments, led to the decrease in gross margin. For the full year, the company reported total revenue of $60,594,000 against $28,181,000 a year ago. Operating loss was $62,854,000 against $77,543,000 a year ago. Net loss was $66,160,000 or $0.94 per basic and diluted share against net loss of $79,293,000 or $1.26 per basic and diluted share a year ago. The company expects its strengthened market position and broader adoption across multiple application area to drive continued growth in the product and service revenues for 2015. In addition the company expects to earn another $10 million in Roche milestone revenue this year. The company is continuing to amortize a portion of the initial $35 million collected from Roche each quarter so that in total, expects to record at least as much revenue from the Roche collaboration in 2015 as the company recorded in 2014. As a result, the company is forecasting at least 20% growth in total revenue for the year. The company expects its total operating expense to increase approximately 10% over last year. The company expects total revenue in the first quarter to decrease sequentially from fourth quarter, however, the company is targeting significant growth in revenue this quarter compared with first quarter of last year.

Pacific Biosciences of California, Inc., Q4 2014 Earnings Call, Feb 03, 2015

Pacific Biosciences of California, Inc., Q4 2014 Earnings Call, Feb 03, 2015

Pacific Biosciences of California, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 10:00 AM

Pacific Biosciences of California, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 10:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Michael W. Hunkapiller, Executive Chairman, Chief Executive Officer, President and Member of Compensation Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
P09:GR €5.55 EUR -0.432

P09 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $3.06 USD +0.01
Luminex Corp $15.74 USD -0.23
NanoString Technologies Inc $10.51 USD -0.08
Sequenom Inc $3.50 USD -0.02
WaferGen Bio-systems Inc $4.98 USD +0.40
View Industry Companies
 

Industry Analysis

P09

Industry Average

Valuation P09 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.6x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PACIFIC BIOSCIENCES OF CALIF, please visit www.pacificbiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.